NEUREN PHARMACEUTICALS LIMITED - Charts / Financials

1.31%

$17.78

Market Cap $2.240B

Healthcare Biotechnology

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

ASX:PAR

This stock could have something close to a cure for osteoarthritis. Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and foremost to create a superior treatment for osteoarthritis.

REFRESH

Day
Open	$17.83		Day High	$17.99		Day Low	$17.35
Daily Volume	911820

Bids				Sellers
Number	Price	Volume		Number	Price	Volume
2	$17.40	11000		2	$17.80	10070

Directors & Senior Management

Mr. Jonathan Charles Pilcher	Chief Executive Officer, Managing Director, Executive Director
Ms. Lauren Frazer	Chief Financial Officer, Company Secretary
Dr. Clive Blower	Chief Operating Officer
Mr. Larry Glass	Chief Science Officer
Ms. Liza Squires	Chief Medical Officer
Mr. Gerry Zhao	Chief Business Officer
Mr. Patrick Donald Davies	Non-Executive Independent Chairman of the Board
Ms. Dianne Angus	Non-Executive Independent Director
Mr. Joseph Basile	Non-Executive Independent Director
Dr. Jenny Lee Harry	Non-Executive Independent Director

Data source: Refinitiv

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $17.78		Change 0.230(1.31%)		Mkt cap ! $2.240B

Open	High	Low	Value	Volume
$17.83	$17.99	$17.35	$16.12M	911.8K

Buyers (Bids)

No.	Vol.	Price($)
2	11000	$17.40

Sellers (Offers)

Price($)	Vol.	No.
$17.80	10070	2

View Market Depth

No.	Vol.	Price($)
2	11000	17.400
2	2732	17.300
1	300	17.100
1	58	17.060
1	10	17.040

Price($)	Vol.	No.
17.800	70	1
17.940	566	1
17.990	73	1
18.000	4313	4
18.100	611	2

Last trade - 16.10pm 08/08/2025 (20 minute delay)

NEU (ASX) Chart

NEUREN PHARMACEUTICALS LIMITED - Charts / Financials

Directors & Senior Management

Buyers (Bids)

Sellers (Offers)

Top Stories